Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dapagliflozin Effect on Erythropoiesis and Physical Fitness in Patients With Type 2 Diabetes
NCT03423355Phase 4Withdrawn
- Sponsor
- University Hospital Tübingen
- Start
- Sep 2021
- Primary completion
- Mar 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of dapagliflozin in type 2 diabetes mellitus (T2DM), sponsored by University Hospital Tübingen. Planned start Sep 2021; status: withdrawn.
02
Drugs
dapagliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT03423355.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03423355.